Top Medical News
21 hours ago
The use of thiazides appears to contribute to an increased risk of stroke in patients with type 2 diabetes, specifically in those receiving intensive blood pressure (BP) control, a recent study has found.
Diabetes mellitus carries an increased hazard of ischaemic stroke in patients with or without atrial fibrillation even in the absence of coronary artery disease (CAD), a study has found.
Rachel Soon, Yesterday

Diabetes is a complex disease that is best treated by a multidisciplinary team of healthcare professionals. But even with their help, patients with diabetes often struggle to comply with a bewildering array of medications at home. In conjunction with World Diabetes Day on 14 November, Lim Phei Ching speaks with MIMS about her experiences in 13 years as a pharmacist in Hospital Pulau Pinang’s Diabetes Medication Therapy Adherence Clinic (DMTAC).

Rachel Soon, Yesterday

In conjunction with World Diabetes Day on 14 November, diabetes solutions provider Ascensia Diabetes Care and local retail pharmacy chain Alpro Pharmacy have launched a first-in-kind diabetes management programme in Malaysia.

Roshini Claire Anthony, Yesterday

Patients with type 2 diabetes (T2D) and severe obesity may have a greater chance of complete T2D remission 1 year after gastric bypass rather than sleeve gastrectomy, according to results of the Oseberg* trial.

Consumption of soy products, but not soy milk, is associated with fewer vasomotor menopausal symptoms (VMS) among middle-aged women, results from a pooled analysis of five studies from the InterLACE* consortium have shown.
Ceritinib use appears to carry a significant risk of developing hyperglycaemia, a new Japan study has found.
Special Reports
11 Sep 2019
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
24 Apr 2019
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
29 Mar 2019
Dapagliflozin 5 mg and 10 mg FC tab
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
31 May 2018
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
Conference Reports
Roshini Claire Anthony, 31 Oct 2019

Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.

Audrey Abella, 25 Oct 2019
The novel dual GIP* and GLP-1** receptor agonist tirzepatide demonstrated clinically meaningful improvements in glycaemic control and weight loss in patients with type 2 diabetes (T2D), according to data presented at EASD 2019.
Audrey Abella, 23 Oct 2019
The addition of the dual SGLT*1 and SGLT2 inhibitor sotagliflozin to insulin led to improvements in glycaemic control, body weight, and systolic blood pressure (SBP) in overweight/obese individuals with type 1 diabetes (T1D), according to a post hoc analysis presented at EASD 2019.

Roshini Claire Anthony, 19 Oct 2019

In patients with type 2 diabetes (T2D) inadequately controlled on metformin, semaglutide may have a greater impact than canagliflozin in reducing HbA1c levels and bodyweight, according to the phase IIIb SUSTAIN 8* trial presented at EASD 2019.

Roshini Claire Anthony, 04 Oct 2019

The incidence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), or nonfatal stroke (three-point MACE*) was comparable in individuals with early stage type 2 diabetes (T2D) who received the DPP-4** inhibitor linagliptin or the sulfonylurea glimepiride in addition to usual care, according to results of the CAROLINA*** trial.

Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 30 Sep 2019

Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download